PET/CT Diagnostik des Prostatakarzinoms mit Bombesinanaloga

Translated title of the contribution: PET/CT diagnostics of prostata cancer using Bombesinanaloga

Research output: Contribution to journalArticlepeer-review


Human prostate cancers frequently express the gastrin releasing peptide receptor (GRPr), also known as Bombesin type-2 receptor. In contrast, expression levels of GRPr are low in normal and hyperplastic prostate tissue. Metabolically stable GRPr antagonists, labeled with radiometals have shown high tumor uptake in preclinical models of prostate cancer. Furthermore, these ligands demonstrated rapid clearance from normal tissues. Clinical studies have confirmed this favorable biodistribution of GRPr antagonists in patients. These studies have also provided first data on the sensitivity of GRPr PET for detection of primary and metastatic prostate cancer. This review provides a brief overview on the clinical development of GRPr ligands for PET imaging (and potentially also for radionuclide therapy) of prostate cancer.

Translated title of the contributionPET/CT diagnostics of prostata cancer using Bombesinanaloga
Original languageGerman
Pages (from-to)283-287
Number of pages5
JournalTumor Diagnostik und Therapie
Issue number5
StatePublished - 18 Aug 2015
Externally publishedYes


Dive into the research topics of 'PET/CT diagnostics of prostata cancer using Bombesinanaloga'. Together they form a unique fingerprint.

Cite this